## Abstract The present investigation was performed to study the adsorption behavior of growth factors and their release characteristics from biodegradable implants in an __in vitro__ study. We investigated the stability of growth factors administered on various scaffolds. We used porous tricalcium
Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors
✍ Scribed by Schmidmaier, G. ;Wildemann, B. ;Stemberger, A. ;Haas, N. P. ;Raschke, M.
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 96 KB
- Volume
- 58
- Category
- Article
- ISSN
- 0021-9304
- DOI
- 10.1002/jbm.1040
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Local application of growth factors like insulin like growth factor‐I (IGF‐I) and transforming growth factor‐beta 1 (TGF‐β1) from a biodegradable thin layer of poly(D,L‐lactide) (PDLLA) coated implants could stimulate fracture healing. A new “cold coating technique” for metallic implants was established to produce a biodegradable coating with a high mechanical stability that provides a continuous release of incorporated growth factors. The properties of this bioactive coating were investigated in vitro and in vivo. Scanning electron microscope analysis revealed a coating thickness of in average 14.8 μm on titanium and 10.7 μm on steel wires. Intramedullary implantation and extraction experiments depicted a loss of PDLLA coating from titanium and steel implants of less than 5%. After explantation of the implants, the coating displayed a complete and regular layer without any defects of PDLLA uncovering the metallic surface. Smear tests demonstrate that the coating can be performed under sterile conditions. The PDLLA depicted a reduction of about 8% within 6 weeks in vitro and in vivo. The growth factors were incorporated in a stable form and demonstrated a loss of stability of less than 3% within 42 days and less than 5% within one year. In an elution experiment, 54% IGF‐I and 48% TGF‐β1 were released within the first 48 h. After 42 days, 76% of IGF‐I and 71% of TGF‐β1 were detected in the elution fluid by ELISA. Comparable results were obtained in the in vivo experiments after 42 days. © 2001 John Wiley & Sons, Inc. J Biomed Mater Res (Appl Biomater) 58: 449–455, 2001
📜 SIMILAR VOLUMES
## Abstract Paclitaxel is one of the best antineoplastic drugs found in nature in the past decades, which has excellent therapeutic effects against a wide spectrum of cancers. Because of its high hydrophobicity, Cremophor EL has to be used as adjuvant in its clinical dosage form (Taxol®), which has
Poly(D,L-lactide) (PDLLA) amphiphilic block copolymers were employed as emulsifiers in the preparation of PDLLA nanoparticles by an oil/water emulsion solvent evaporation technique. The surface-active properties of poly(N-vinyl-pyrrolidone)-blockpoly(D,L-lactide) (PVP-b-PDLLA) toward the biphasic sy
## Abstract Bisphosphonates such as zoledronic acid (ZOL) are used in diseases associated with osteoclast‐mediated bone loss. However, their antiresorptive activity is partly due to their effect on osteoblasts. Local application might increase the therapeutical fence and their local efficiency and
## Abstract The antiresorptive activity of bisphosphonates such as zoledronic acid (ZOL) has been shown __in vitro__ to be because of their effect on osteoclasts and osteoblasts. However, whether the effect of ZOL on monocultures might be reproducible on cocultures and whether cell interactions mig